Episode Details

In episode 65 of Hims House, Jonathan Stern talks with Mansi Hukmani, founder of Chief Longevity Officer, about how peptide culture moved from biohacker circles into the next big frontier for telehealth. Mansi explains how New York, San Francisco, London, and Dubai each approach longevity culture differently, and why distrust in traditional healthcare has helped peptides feel more like a movement than a product category. They discuss her own experience with retatrutide, the coming FDA regulatory milestones, and why reclassification could unleash a wave of clinics, compounders, and telehealth players. The conversation then turns to the real bottleneck: supply chain control, especially China’s dominance in protected amino acids and peptide synthesis. Mansi argues the winners may not be first to market, but first to secure manufacturing, data, and trust at scale.

02:09 - The #1 peptide substacker

03:45 - Inside peptide culture

06:30 - NAD+ shots and different form factors

08:20 - Peptide culture across cities

10:54 - Dubai’s longevity gold rush

12:21 - Why peptides feel a little like crypto

16:41 - Mansi’s peptide experiments

19:50 - FDA timeline for peptide reclassification

24:46 - Why supply chain wins

26:11 - The synthesis bottleneck

28:15 - China’s scale advantage

30:29 - Why Hims bought CS Bio

31:39 - State laws

33:57 - Who wins the peptide rush

36:51 - Pricing power, tariffs, and trust

41:53 - Why gray markets persist

45:01 - Peptides with real LTV

47:51 - The Flatiron Health for peptides

Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.